Cerebrovascular events hang up Cytori trials; shares plunge
This article was originally published in Scrip
Executive Summary
Shares of Cytori Therapeutics fell over a cliff on 6 August, tumbling about 44%, after the company revealed it enrollment of its ATHENA and ATHENA II trials had been halted in light of reports of adverse cerebrovascular events in patients receiving the firm's experimental adipose-derived regenerative cells (ADRCs) treatment.